ARTICLE | Translation in Brief
Gene therapy rising
Ophthotech’s PPPs are part of a growing trend for preclinical gene therapy deals
November 14, 2018 11:58 PM UTC
Ophthotech Corp. (NASDAQ:OPHT) closed its third gene therapy-focused public-private partnership of the year on Oct. 31, and is one of more than a dozen companies that have licensed preclinical gene therapies this year from academics.
For gene therapies, manufacturing considerations remain one of the greatest challenges, particularly as programs transition from animal proof-of-concept to IND-enabling studies. By licensing gene therapy programs at the preclinical stage, Ophthotech and others could help overcome the manufacturing bottleneck (see “Academia’s Manufacturing Problem”)...